Accueil・Liste d'Actions・Anavex Life Sciences Corp

Anavex Life Sciences Corp

Ouvert

SecteurSoins de santé

3.08 -3.45

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

3.16

Max

3.29

Chiffres clés
By Trading Economics
Revenu	4.1M -5.7M
BPA	0.08
Employés	34
EBITDA	-821K -6.5M

Dividendes
By Acuity
Prochains Résultats	24 nov. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	57M 288M
Ouverture précédente	6.53
Clôture précédente	3.08

Sentiment de l'Actualité

By Acuity

73%

27%

312 / 340 Classement par Healthcare

Anavex Life Sciences Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

26 août 2026, 23:41 UTC

Anavex Life Sciences Corp shares are higher during after-market hours, supported by a broader market trend. No specific company news was identified.

25 août 2026, 20:07 UTC

Event

News

Anavex Life Sciences reported Q3 2026 net income of $7.8 million, returning to profitability. Shares are trading higher following the financial results and pipeline updates.

24 août 2026, 23:11 UTC

Anavex Life Sciences Corp shares are higher in after-market trading, building on positive momentum from Monday's close and a strong one-month performance.

21 août 2026, 20:06 UTC

Anavex Life Sciences Corp is gaining amid broader market strength, reflecting a robust performance in biotechnology and positive investor sentiment despite no specific company news.

20 août 2026, 20:01 UTC

Anavex Life Sciences Corp shares are lower today, driven by significant weakness in the Biotechnology sub-sector and broader trends affecting the sector.

19 août 2026, 19:44 UTC

Anavex Life Sciences Corp is trading sharply higher, reaching a session high and maintaining a position above its 20-day moving average. No specific news was identified.

17 août 2026, 19:46 UTC

News

Anavex Life Sciences has communicated with stockholders about director nominees amid a "Hold" rating from analysts. Shares are trading roughly flat since Friday's close.

14 août 2026, 20:13 UTC

Anavex Life Sciences shares are lower in after-market hours, influenced by disappointing U.S. retail sales data and declining consumer sentiment.

13 août 2026, 22:51 UTC

Anavex Life Sciences Corp shares are lower in after-market hours, continuing a trend of declines over three consecutive sessions. No specific news was identified.

12 août 2026, 19:46 UTC

Anavex Life Sciences Corp shares are lower today, continuing a decline since Tuesday's close, despite remaining above the 20-day moving average.

11 août 2026, 23:22 UTC

Anavex Life Sciences Corp is trading lower in after-market hours with no specific news. The stock remains well above its 20-day moving average.

10 août 2026, 19:46 UTC

Anavex Life Sciences is trading higher today, despite no specific news. Broader market sentiment is influenced by upcoming inflation data and Fed policy expectations.

7 août 2026, 22:16 UTC

Anavex Life Sciences Corp is higher in after-market trading, continuing a trend of gains over the last seven sessions, despite no specific news identified.

6 août 2026, 23:51 UTC

Anavex Life Sciences Corp is rising in after-market trading, reaching a high shortly after the market closed, despite no specific news driving the increase.

5 août 2026, 21:01 UTC

Anavex Life Sciences shares fell in after-market trading, declining significantly despite being above its 20-day moving average and near the top of its one-month range.

4 août 2026, 19:51 UTC

Anavex Life Sciences Corp is rising amid broader market strength and a decline in crude oil prices, despite pulling back from earlier session highs.

3 août 2026, 20:02 UTC

News

Anavex Life Sciences Corp announces board changes amid a proxy fight, urging stockholders to reject PVG Asset Management's attempt to replace the board. Shares are higher.

30 juil. 2026, 19:39 UTC

Event

Anavex Life Sciences reported Q2 earnings of -$0.06 per share, beating expectations. Shares remain higher since Wednesday's close despite pulling back from session highs.

29 juil. 2026, 22:31 UTC

Anavex Life Sciences Corp shares are higher in after-market trading, reflecting broader market gains following the Federal Reserve's decision to maintain interest rates.

28 juil. 2026, 21:01 UTC

Anavex Life Sciences Corp shares are lower in after-market hours, currently 1.45% below their 20-day moving average. No specific news was identified.

27 juil. 2026, 20:07 UTC

Anavex Life Sciences Corp shares are higher during Monday's session, maintaining gains since Friday amid broader market trends and easing geopolitical tensions.

24 juil. 2026, 17:46 UTC

Anavex Life Sciences Corp shares are lower today, continuing a decline since Thursday's close, with no specific news identified to explain the move.

21 juil. 2026, 19:51 UTC

Anavex Life Sciences is rising during Tuesday's session, recovering from a pre-market low. Broader market sentiment is supported by positive earnings from General Motors and Novartis.

Comparaison

Variation de prix

Anavex Life Sciences Corp prévision

Note du Consensus

By TipRanks

0 ratings

Achat

Maintien

Vente

Basé sur 0 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

312 / 340Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.